StreetInsider.com News Articles

TD Cowen Starts Stevanato Group S.p.A. (STVN) at Buy

Tue, 16 Jun 2026 09:48:31 -0400

(Updated - June 16, 2026 9:48 AM EDT)

TD Cowen analyst Chad Wiatrowski initiates coverage on Stevanato Group S.p.A. (NYSE: STVN) with a Buy rating and a price target of $25.00.

The analyst commented, "We initiate on Stevanato with a Buy rating and $25 PT because we believe the stock reflects too much skepticism around ramp costs and not enough of the improving mix, margin, and free cash flow story. In our view, 2026 marks the shift from buildout drag to visible execution, with biologics, GLP-1s, Annex-1, and premium containment supporting a re-rating as results and cash flow become clearer."

For an

TD Cowen Starts Stevanato Group S.p.A. (STVN) at Buy

Tue, 16 Jun 2026 09:48:31 -0400

(Updated - June 16, 2026 9:48 AM EDT)

TD Cowen analyst Chad Wiatrowski initiates coverage on Stevanato Group S.p.A. (NYSE: STVN) with a Buy rating and a price target of $25.00.

For an

Stevanato Group launches Deora pen injector for diabetes treatments

Mon, 08 Jun 2026 06:31:25 -0400

Stevanato Group S.p.A. (NYSE: STVN) announced the introduction of Deora, a pen injector platform designed for subcutaneous drug delivery in diabetes and weight management therapies. The device targets incretin-based therapies and supports originator and biosimilar drug development programs.

The multi-use, fixed-dose pen injector features a pull-push mechanism where users pull to set the dose and push to inject. This design eliminates manual dose selection and accommodates fixed-dose volumes up to 0.75 mL. The platform is compatible with standard 1.5 mL and 3 mL cartridges.

"With Deora, we are broadening our product offering in therapeutic areas experiencing strong global demand and favorable market

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Mon, 08 Jun 2026 06:30:00 -0400

The fixed-dose, multi-use pen injector platform features a pull-push mechanism designed to reduce use error while supporting delivery volumes up to 0.75 mL

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608096966/en/

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608096966/en/

Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders (“Shareholders’ Meeting”) held virtually on May 26, 2026, have passed.